Product Overview

Material

Half-life

Average size of microspheres

Size distribution of microspheres

Indication

Dosage

Mechanism of action

Package size

Amilomer (DSM35/50)

30–40 minutes

50 7 µm    

Min 95% 20–90 µm

Max 4,0% > 90 µm

Max 2,5% < 20 µm 

Transarterial chemoembolization (TACE) of 
inoperable liver and lung tumors
    

2,5 – 7,5 ml (150–450 mg), depending on tumor size and vascularization, arterial blood flow and aarteriovenous shunt volume. Maximum dose of 15 ml (900 mg) possible in individual cases

Reduction of blood flow causes short term ischemia in addition to a local concentration increase of the simultaneously applied cytostatic agent.

450 mg Amilomer in 7.5 ml saline solution  

Product Features

  • Good tolerability [1]
  • Optimum degradation time [2]
  • Excellent necrosis rates [3]
  • Can be combined with other treatment methods [4]
  • Repeatable TACE [5]
  • No particle loading: not limited in the choice of active ingredient for DSM-TACE

 

Movie

Product information and mechanism of action

[1] Niessen et al. (2014): Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of
      hepatocellular carcinoma. J Vasc Interv Radiol 25(2), 240–247; 
[2] Wiggermann et al. (2012): Degradable starch microspheres transarterial chemoembolisation (DSM-TACE) of HCC: Dynamic Contrast-
      Enhanced Ultrasonography (DCE-US) based evaluation of therapeutic efficacy using a novel perfusion software. Clin Hemorheol
      Microcirc 52(2–4), 123–129;
[3] Altomonte et al. (2008): Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats.
      Hepatology 48(6), 1864–1873;
[4] Vogl et al. (2014): Neoadjuvant TACE before laser induced thermotherapy (LITT) in the treatment of non-colorectal non-breast cancer
      liver metastases: feasibility and survival rates. Eur J Radiol 83(10), 1804–1810; 
[5] Farshid et al. (2013): Repetitive chemoembolization of hypovascular liver metastases from the most common primary sites. Future Oncol
      9(3)´, 419–426

Products EmboCept® S